On Thursday, Celgene reported on a trial it was running of Revlimid as a treatment for B-cell chronic lymphocytic leukemia, as it looks to expand uses for the drug.
The company said 34 of 210 patients treated with Revlimid died, compared with 18 deaths in 211 patients treated with Leukeran. The cause of the imbalance in deaths hasn't been identified.
Revlimid is approved in combination with Dexamethasone, a synthetic adrenocortical steroid, for the treatment of patients with multiple myeloma who have received at least one prior therapy, in nearly 70 countries. It is also approved in the U.S. for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies.
Michael Yee, analyst with RBC Capital Markets, said Celgene's program cancellation is a "positive" for Pharmacyclics (PCYC), as its drug Ibrutinib, used in the treatment of various types of cancers, "is well liked by doctors." Shares of Pharmacyclics were up nearly 1% in afternoon trading Thursday, near 106.
One would think .Celgene said it had halted a trial testing Revlimid as a first-line treatment for elderly patients with B-cell chronic lymphocytic leukemia, or CLL. The reason: almost twice as many deaths in Revlimid patients as in control patients.
Progression-free Survival 96% in CLL With Ibrutinib..Sound good IMO